We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.07B
AUM Growth
+$214M
Cap. Flow
+$110M
Cap. Flow %
10.26%
Top 10 Hldgs %
29.29%
Holding
121
New
28
Increased
49
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$25.5M
2
RDUS
Radius Health, Inc.
RDUS
+$18M
3
LLY icon
Eli Lilly
LLY
+$16.4M
4
BHC icon
Bausch Health
BHC
+$16.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$12.9M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$30.2M
2
MRK icon
Merck
MRK
+$25.6M
3
STJ
St Jude Medical
STJ
+$21.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$18.6M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.22%
2 Financials 1.56%
3 Industrials 0.97%
4 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
76
Pacira BioSciences
PCRX
$997M
$4.51M 0.42%
+50,750
New +$5.15M
JAZZ icon
77
Jazz Pharmaceuticals
JAZZ
$16.7B
$4.49M 0.42%
26,000
+1,000
+4% +$172K
ILMN icon
78
Illumina
ILMN
$28.4B
$4.46M 0.42%
24,672
-6,682
-21% -$1.26M
CERN
79
DELISTED
Cerner Corp
CERN
$4.4M 0.41%
+60,000
New +$4.15M
CO
80
DELISTED
Global Cord Blood Corporation
CO
$4.24M 0.4%
830,000
+8,000
+1% +$39.4K
ASMB icon
81
Assembly Biosciences
ASMB
$529M
$4.2M 0.39%
+26,458
New +$3.58M
KITE
82
DELISTED
Kite Pharma, Inc.
KITE
$4.12M 0.39%
71,474
-43,000
-38% -$2.88M
CSLT
83
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$4.07M 0.38%
525,000
+264,800
+102% +$2.27M
BMRN icon
84
BioMarin Pharmaceuticals
BMRN
$12.4B
$4.05M 0.38%
+32,500
New +$3.44M
TTPH
85
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$3.76M 0.35%
+5,125
New +$3.85M
MGNX icon
86
MacroGenics
MGNX
$257M
$3.65M 0.34%
+116,500
New +$3.95M
FPRX
87
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.11M 0.29%
136,000
+16,000
+13% +$404K
BLUE
88
DELISTED
bluebird bio
BLUE
$3.02M 0.28%
1,930
– –
INFI
89
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.01M 0.28%
215,000
+5,000
+2% +$76.4K
ADVM
90
DELISTED
Adverum Biotechnologies
ADVM
$2.86M 0.27%
+7,050
New +$2.98M
BNFT
91
DELISTED
Benefitfocus, Inc.
BNFT
$2.76M 0.26%
+75,000
New +$2.24M
CLLS
92
Cellectis
CLLS
$285M
$2.59M 0.24%
+75,000
New +$2.72M
ONCE
93
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.57M 0.24%
+33,106
New +$1.91M
PTCT icon
94
PTC Therapeutics
PTCT
$6.12B
$2.46M 0.23%
+40,500
New +$2.47M
XNPT
95
DELISTED
XENOPORT, INC.
XNPT
$2.21M 0.21%
310,000
+75,000
+32% +$582K
NVTA
96
DELISTED
Invitae Corporation
NVTA
$2.1M 0.2%
+125,000
New +$2.31M
TRIV
97
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$2.08M 0.19%
198,000
– –
KIN
98
DELISTED
Kindred Biosciences, Inc.
KIN
$1.96M 0.18%
275,000
– –
ANTH
99
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.9M 0.18%
+53,125
New +$1.57M
RPTP
100
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$1.69M 0.16%
+155,000
New +$1.58M
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rock Springs Capital Management held 121 positions worth $1.07B, up 25% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $110M of net new capital in Q1 2015, opening 28 new positions and adding to 49 existing holdings. Its largest new stake was Pfizer: 801,040 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $3.37M trimmed.

  • Rock Springs Capital Management's largest Q1 2015 buy was Pfizer: 801,040 shares worth $26.4M.
  • Rock Springs Capital Management added most to Bausch Health in Q1 2015, an estimated $16.3M increase.
  • Rock Springs Capital Management's biggest Q1 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $3.37M.
  • Rock Springs Capital Management fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $30.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.07B portfolio in Q1 2015.
  • Rock Springs Capital Management opened 28 new positions and closed 16 in Q1 2015.
  • Rock Springs Capital Management's portfolio value rose 25% quarter-over-quarter to $1.07B.

Based on Rock Springs Capital Management's 13F filing for Q1 2015, filed 15 May 2015.